NCT02939300: Ipilimumab and Nivolumab in Leptomeningeal Metastases

NCT02939300
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients with prior systemic treatment with an anti-CTLA4 antibody
https://ClinicalTrials.gov/show/NCT02939300

Comments are closed.

Up ↑